RPh201

DRUG4 trials

Sponsors

Hadassah Medical Organization, Regenera Pharma Ltd

Conditions

Chronic Vegetative StateMild to Moderate Dementia Due to Alzheimer's DiseaseNon-arteritic Ischemic Optic NeuropathyOptic Nerve InjuriesWith or Without Coexisting Cerebrovascular Disease

Phase 1

The Impact of RPh201 on CVS Patients: Clinical and fMRI Measurements

WithdrawnNCT01417299

Hadassah Medical OrganizationChronic Vegetative State

Start: 2011-10-31End: 2018-10-31Updated: 2015-09-22

The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study

SuspendedNCT01438684

Hadassah Medical OrganizationChronic Vegetative State

Start: 2012-09-30End: 2020-10-31Target: 10Updated: 2018-02-06

Phase 2

Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

CompletedNCT02045212

Regenera Pharma LtdNon-arteritic Ischemic Optic Neuropathy, Optic Nerve Injuries

Start: 2014-02-28End: 2016-12-31Updated: 2020-03-19

A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

CompletedNCT03462121

Regenera Pharma LtdMild to Moderate Dementia Due to Alzheimer's Disease, With or Without Coexisting Cerebrovascular Disease

Start: 2018-03-01End: 2020-03-30Updated: 2020-04-30

Related Papers

Randomized Controlled Phase 2a Study of RPh201 in Previous Nonarteritic Anterior Ischemic Optic Neuropathy

Journal of Neuro-Ophthalmology2019-05-0615 citations